JP2010501596A - 抗体含有組成物を用いた非感染性の病状の処置および／または予防 - Google Patents

抗体含有組成物を用いた非感染性の病状の処置および／または予防 Download PDF

Info

Publication number
JP2010501596A
JP2010501596A JP2009525863A JP2009525863A JP2010501596A JP 2010501596 A JP2010501596 A JP 2010501596A JP 2009525863 A JP2009525863 A JP 2009525863A JP 2009525863 A JP2009525863 A JP 2009525863A JP 2010501596 A JP2010501596 A JP 2010501596A
Authority
JP
Japan
Prior art keywords
cancer
antibody
ephb4
condition
esophageal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009525863A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010501596A5 (https=
Inventor
アントニー・ウィリアム スカメル，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ACN 135 493 391 Pty Ltd Trustee For Conca Unit Trust AS
Original Assignee
ACN 135 493 391 Pty Ltd Trustee For Conca Unit Trust AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006904752A external-priority patent/AU2006904752A0/en
Application filed by ACN 135 493 391 Pty Ltd Trustee For Conca Unit Trust AS filed Critical ACN 135 493 391 Pty Ltd Trustee For Conca Unit Trust AS
Publication of JP2010501596A publication Critical patent/JP2010501596A/ja
Publication of JP2010501596A5 publication Critical patent/JP2010501596A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/04—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2009525863A 2006-08-31 2007-08-31 抗体含有組成物を用いた非感染性の病状の処置および／または予防 Pending JP2010501596A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2006904752A AU2006904752A0 (en) 2006-08-31 Uses for Antibodies
PCT/AU2007/001282 WO2008025099A1 (en) 2006-08-31 2007-08-31 Treatment and/or prevention of non-infectious medical conditions using antibody-containing compositions

Publications (2)

Publication Number Publication Date
JP2010501596A true JP2010501596A (ja) 2010-01-21
JP2010501596A5 JP2010501596A5 (https=) 2010-09-16

Family

ID=39135433

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009525863A Pending JP2010501596A (ja) 2006-08-31 2007-08-31 抗体含有組成物を用いた非感染性の病状の処置および／または予防

Country Status (8)

Country Link
US (2) US20100297140A1 (https=)
EP (1) EP2061510B1 (https=)
JP (1) JP2010501596A (https=)
CN (1) CN101626784B (https=)
AU (1) AU2007291891B2 (https=)
DK (1) DK2061510T3 (https=)
NZ (1) NZ575918A (https=)
WO (1) WO2008025099A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014507117A (ja) * 2010-12-08 2014-03-27 ステム・セントレクス・インコーポレーテッド 新規モジュレーターと使用の方法
US9381205B2 (en) 2013-11-04 2016-07-05 Pfizer, Inc. Anti-EFNA4 antibody-drug conjugates

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2725035A1 (en) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
CA2760096C (en) 2009-04-27 2018-10-30 Immuron Limited Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder.
JP2011026252A (ja) * 2009-07-27 2011-02-10 Kitasato Institute 上皮成長因子受容体に対する卵黄抗体およびその用途
WO2012023051A2 (en) 2010-08-17 2012-02-23 Immuron Ltd. Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder
MY164281A (en) 2010-11-23 2017-11-30 Pantheryx Inc Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications
WO2012098256A1 (en) * 2011-01-21 2012-07-26 Université De La Méditerranée Aix - Marseille Ii Anti-cd146 auto-antibodies and uses thereof
DE102011006809A1 (de) 2011-04-05 2012-10-11 Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten
EP2786156A2 (en) * 2011-11-30 2014-10-08 AbbVie Deutschland GmbH & Co KG Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
RO130965A8 (ro) * 2015-10-16 2017-06-30 Romvac Company S.A. Producerea şi utilizarea oului hiperimun personalizat () în tratamentul psoriazisului
US10792320B2 (en) * 2018-03-28 2020-10-06 Michael Alan Beller Methods for treatment of bladder dysfunction
WO2020176637A1 (en) 2019-02-26 2020-09-03 Pantheryx, Inc. Compositions for management of disorders of the gastrointestinal tract
US11319382B1 (en) 2021-06-28 2022-05-03 King Abdulaziz University Methods for producing and using IgY antibodies targeting the middle east respiratory syndrome coronavirus spike protein to treat or prevent MERS-CoV infection

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001501622A (ja) * 1996-10-02 2001-02-06 オビミュン インコーポレイテッド 病気を治療するための鶏卵黄抗体の経口投与
CN1377894A (zh) * 2002-04-23 2002-11-06 郭占军 蛋黄抗癌抗体制备方法及其应用
JP2006517906A (ja) * 2002-09-16 2006-08-03 ザ クイーン エリザベス ホスピタル リサーチ ファンデーション インコーポレーテッド 癌制御方法
WO2007026689A1 (ja) * 2005-08-29 2007-03-08 Japan Science And Technology Agency ダチョウを用いた抗体、及びその作製方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3911108A (en) * 1973-02-14 1975-10-07 Diamond Shamrock Corp Process of producing bovine milk products containing specific antibodies
AUPN642795A0 (en) * 1995-11-08 1995-11-30 Northfield Laboratories Pty Ltd Dairy compositions and methods of preparing same
AU2115799A (en) * 1998-01-19 1999-08-02 Dcv, Inc. Composition and method for treatment and prevention of arthritis and/or autoimmune diseases
WO1999064069A1 (en) * 1998-06-10 1999-12-16 Ophidian Pharmaceuticals, Inc. Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease
CN1163511C (zh) * 1999-10-22 2004-08-25 徐永华 鸡卵黄抗白细胞介素-8抗体、制备方法及其应用
CN1303889A (zh) 1999-12-20 2001-07-18 陶氏康宁东丽硅氧烷株式会社 用于嵌件模塑或双模腔模塑的硅橡胶组合物
JP2005298332A (ja) * 2000-09-28 2005-10-27 Shibayagi:Kk 過剰自己抗体産生抑制物質、その製造法およびその使用方法
US20050175597A1 (en) * 2002-03-21 2005-08-11 Rawlin Grant T. Compositions containing labile bioactive materials and mammalian colostrum, methods of preparation and treatment
CN1199672C (zh) 2002-04-17 2005-05-04 李永忠 一套预防与治疗癌症中成药
JP4264894B2 (ja) * 2004-03-01 2009-05-20 三菱自動車工業株式会社 エアボックス付きグローブボックス
CN101072797B (zh) * 2004-03-12 2012-05-09 瓦斯基因治疗公司 结合ephb4、抑制血管发生和肿瘤生长的抗体
AU2005299767A1 (en) * 2004-10-21 2006-05-04 The Penn State Research Foundation Eph receptor tumor biomarkers
JP2008537673A (ja) * 2005-01-31 2008-09-25 ジェネンテック・インコーポレーテッド 抗ｅｐｈｂ２抗体とその使用方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001501622A (ja) * 1996-10-02 2001-02-06 オビミュン インコーポレイテッド 病気を治療するための鶏卵黄抗体の経口投与
CN1377894A (zh) * 2002-04-23 2002-11-06 郭占军 蛋黄抗癌抗体制备方法及其应用
JP2006517906A (ja) * 2002-09-16 2006-08-03 ザ クイーン エリザベス ホスピタル リサーチ ファンデーション インコーポレーテッド 癌制御方法
WO2007026689A1 (ja) * 2005-08-29 2007-03-08 Japan Science And Technology Agency ダチョウを用いた抗体、及びその作製方法

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014507117A (ja) * 2010-12-08 2014-03-27 ステム・セントレクス・インコーポレーテッド 新規モジュレーターと使用の方法
US9765136B2 (en) 2010-12-08 2017-09-19 Abbvie Stemcentrx Llc Modulators and methods of use
JP2018008949A (ja) * 2010-12-08 2018-01-18 アッヴィ・ステムセントリックス・エルエルシー 新規モジュレーターと使用の方法
US9969798B2 (en) 2010-12-08 2018-05-15 AbbVie Stemcentrx LLP Modulators and methods of use
US9381205B2 (en) 2013-11-04 2016-07-05 Pfizer, Inc. Anti-EFNA4 antibody-drug conjugates
US9872922B2 (en) 2013-11-04 2018-01-23 Pfizer Inc. Anti-EFNA4 antibody-drug conjugates

Also Published As

Publication number Publication date
AU2007291891B2 (en) 2013-10-31
EP2061510B1 (en) 2016-06-22
CN101626784B (zh) 2013-07-17
US20100297140A1 (en) 2010-11-25
DK2061510T3 (en) 2016-09-05
CN101626784A (zh) 2010-01-13
EP2061510A1 (en) 2009-05-27
US20130295109A1 (en) 2013-11-07
NZ575918A (en) 2012-03-30
WO2008025099A1 (en) 2008-03-06
US8834872B2 (en) 2014-09-16
AU2007291891A1 (en) 2008-03-06
EP2061510A4 (en) 2011-01-05

Similar Documents

Publication Publication Date Title
US8834872B2 (en) Uses of antibodies
TWI852695B (zh) 抗體-藥物結合物之用途
JP6359492B2 (ja) 抗ＩＬ−１α抗体による癌の処置方法
RU2680717C2 (ru) Олигопептиды металлопротеиназ и их терапевтическое применение
TW201815423A (zh) 免疫性／治療性聚醣組合物及其用途
AU2017201718A1 (en) Glycoproteins having lipid mobilizing properties and therapeutic uses thereof
JP2022512709A (ja) 炎症性疾患及び自己免疫疾患を処置する組成物及び方法
JP7216965B2 (ja) Ｓ１００ａ９を標的とする免疫原性組成物
US20180340027A1 (en) Milk fat globule epidermal growth factor 8 regulates fatty acid uptake
JP2022046576A (ja) 炎症性障害の治療療法
CN114555624A (zh) 抗炎剂
US20090068174A1 (en) Therapeutic alkaline protease compositions and use in facilitating the transport of agents across the gastrointestinal mucosal lining
CA3223191A1 (en) Compositions and methods for diagnosing, detecting and treating eosinophil-related diseases
US8067009B1 (en) Metalloproteinase oligopeptides and their therapeutic use
CN114225025A (zh) 含有益生菌的制剂在治疗肠胃疾病中的应用
CN114225024B (zh) 一种用于治疗疾病的益生菌药物
WO2019045025A1 (ja) ワクチン組成物
US20160193180A1 (en) Composition for preventing and treating immune diseases containing daurinol compound as active ingredient
US10968441B2 (en) Metalloproteinase-9 oligopeptides and their therapeutic use
CN116212026A (zh) 巨噬细胞封闭剂在制备adc药物副反应治疗或预防产品中的用途
JP2011026252A (ja) 上皮成長因子受容体に対する卵黄抗体およびその用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100730

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121203

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130212